Nick Leschly, the well-known CEO in the gene therapy field, is making a comeback with his new company, Altido Therapeutics. The focus of this startup is to bring to market a CAR-T cell therapy that was developed at Massachusetts General Hospital (MGH) for the treatment of glioblastoma, a highly aggressive and typically fatal brain tumor. With a recent $12.5 million seed round led by ARCH Venture, Altido Therapeutics is now aiming to secure a $75 million Series A funding round.
Although the data from the CAR-T treatment are still in the early stages, they have already sparked excitement within the medical community due to the bleak prognosis associated with glioblastoma. Initial results from the trial have shown promising outcomes, with all three of the first patients experiencing significant tumor shrinkage. While two of these patients unfortunately experienced relapse and ultimately passed away, one patient continues to thrive more than 2.5 years after receiving the treatment.
This groundbreaking research and development in CAR-T therapy for glioblastoma holds great potential for transforming the treatment landscape for this devastating disease. The innovative approach taken by Altido Therapeutics, under the leadership of Nick Leschly, showcases the continued commitment to pushing the boundaries of medical science in order to bring hope to patients facing dire diagnoses.
As the journey of Altido Therapeutics unfolds, it will be crucial to closely monitor the progress of their CAR-T therapy and the impact it has on the lives of patients battling glioblastoma. With further advancements and continued support from investors and the scientific community, this novel approach to treating brain tumors could pave the way for a brighter future in the fight against cancer.
